E72.11 Homocystinuria

Name of the Condition

• Homocystinuria (ICD-10 Code: E72.11)

Summary

Homocystinuria is a rare genetic disorder affecting the body’s ability to metabolize the amino acid methionine. This condition disrupts the conversion of homocysteine to cysteine, leading to the accumulation of homocysteine and related compounds in the blood and urine. Clinical effects vary but may involve ocular, skeletal, vascular, and neurological complications. Early diagnosis and management are critical to mitigate long-term sequelae.

Causes

Homocystinuria is primarily caused by genetic mutations that impair enzymes involved in methionine metabolism, most commonly cystathionine beta-synthase (CBS). These mutations disrupt the breakdown of homocysteine, resulting in its accumulation. The condition is typically inherited in an autosomal recessive pattern, requiring two mutated gene copies for manifestation. Mutations in other genes, such as MTHFR or methionine synthase, can also contribute to similar metabolic disruptions.

Risk Factors

• Family history of homocystinuria or related metabolic disorders.
• Consanguinity (parents who are close relatives), increasing the likelihood of inheriting recessive mutations.
• Ethnic or geographic prevalence of specific genetic variants in certain populations.

Symptoms

• Ocular issues such as ectopia lentis (lens dislocation), myopia, or glaucoma.
• Skeletal abnormalities including tall stature, arachnodactyly (long, slender fingers), or osteoporosis.
• Vascular complications like thromboembolism or arterial/venous occlusions.
• Neurological symptoms such as developmental delays, seizures, or intellectual disability.
• Skin findings like malar flush or livedo reticularis.

Diagnosis

Diagnosis typically involves biochemical testing to measure elevated homocysteine levels in blood or urine. Genetic testing may confirm the underlying mutation, particularly in CBS or other associated genes. Newborn screening programs in some regions may detect elevated methionine or homocysteine levels. Additional evaluations, such as ophthalmologic or skeletal imaging, may support clinical suspicion.

Treatment Options

Treatment focuses on reducing homocysteine levels through dietary modifications, such as methionine restriction and supplementation with cysteine or betaine. Vitamin B6 (pyridoxine) may be effective in responsive cases. Regular monitoring of homocysteine, methionine, and nutritional status is essential. Adjunct therapies, including anticoagulants for vascular risk, may be considered based on clinical presentation.

Prognosis and Follow-Up

Prognosis depends on early diagnosis and adherence to treatment. Untreated or late-managed cases may develop severe complications, including vascular events or cognitive impairment. Regular follow-up with metabolic specialists, ophthalmologists, and neurologists is recommended to monitor for ocular, skeletal, and neurological changes. Lifelong management is typically required.

Complications

• Thromboembolic events (e.g., stroke, pulmonary embolism).
• Ocular complications like lens dislocation or retinal detachment.
• Skeletal deformities or osteoporosis.
• Neurological deficits including seizures or intellectual disability.
• Vascular occlusive disease affecting major arteries.

Lifestyle & Prevention

• Adherence to a methionine-restricted diet and prescribed supplements.
• Avoidance of smoking and excessive alcohol, which may exacerbate vascular risk.
• Regular physical activity to support bone health, as guided by a healthcare provider.
• Genetic counseling for families with a history of the condition.

When to Seek Professional Help

Seek immediate medical attention for symptoms of thrombosis (e.g., sudden limb swelling, chest pain) or neurological changes (e.g., confusion, weakness). Routine follow-up is advised for monitoring growth, vision, and metabolic markers. Consult a metabolic specialist for management of dietary or treatment adjustments.

Tips for Medical Coders

Document the underlying genetic cause (e.g., CBS mutation) and clinical manifestations (e.g., ocular, vascular, or neurological findings) to support code assignment. Ensure laboratory results confirming elevated homocysteine or methionine are included in the record. Differentiate from other metabolic disorders by verifying the specific enzyme or pathway affected.